RVMD - a biotech that ending consolidation?

Fundamentals: Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment. Average 1 year target from analysts = 54.

Technical: To allow the stock some fluctuation the stop could be around 40.2 level. Target could be around the previous top - 55-56 area.